Biogen has signed a brace of collaborations to expand its central nervous system (CNS) pipeline, adding new candidates for Alzheimer’s, multiple sclerosis and other neurological diseases.
Bristol-Myers Squibb has agreed a $74 billion deal to merge with Celgene in a deal that will boost its presence in oncology and immunology and make it the fourth-largest drugmaker.
Cancer Research UK and Owlstone Medical have launched a clinical trial to develop a breath test that could detect cancer at an early stage – the first test of its kind to investigate multip
